The agreement allows the HPA to contribute to global polio eradication, while securing a commitment from a major pharma firm to develop use of its technology...Terms include certain milestones and tiered royalty payments to the HPA in return for technology transfer and other licensing rights

Eisai Inc., of Woodcliff Lake, N.J., said the FDA approved Aciphex Sprinkle delayed-release capsules for the treatment of gastroesophageal reflux disease in children, ages 1 to 11, for up to 12 weeks

Ltd., of Yokohama, Japan, to use its cell-loading system to support clinical studies and commercialize treatment of cancer patients...The new partners plan to start clinical trials following an investigational new drug application later this year...Themis plans to start Phase I for both vaccines before the end of this year

In separate news, Astellas signed a deal to access the TSUBAME2.0 supercomputer at the Tokyo Institute of Technology to discover candidates for NTDs caused by dengue virus...In other news, The Nasdaq OMX Stockholm's listing committee approved the listing of NeuroVive's shares

DART will have the option to select a certain number of candidates for additional development...Other candidates currently undergoing tests required for investigational new drug applications with the FDA include an undisclosed iBioLaunch-produced monoclonal antibody and vaccines for anthrax, malaria and yellow fever...The agreement aims to identify inhibitors of a kinase that plays a key role in tissue protection and repair

The manufacturing center will afford GSK the capabilities to eventually manufacture influenza vaccine based on a cell culture line...A pivotal program of Lu AE58054 is planned to start later this year, starting with a Phase III study in patients with mild to moderate Alzheimer's disease testing Lu AE58054 as an adjunct treatment to donepezil

Under terms of the agreement, Actavis can launch its generic version of Crestor 67 days prior to July 8, 2016, the expiration of pediatric exclusivity, at a fee of 39 percent of net sales to AstraZeneca...The FDA granted tentative approval to Actavis' ANDA on June 6, 2011

Deinove's contribution to the subsidiary are the results and intellectual property rights relating to research undertaken on antibiotics, as well as the transfer of the OSEO-ERDF-LR region funding already allocated – €700,000 (US$908,857...would entitle pSivida to a $25 million milestone payment from Alimera and 20 percent of net profits

Ltd., enabling Simcere Vaxtec to resume production of its influenza vaccine

In separate news, Astellas signed a deal to access the TSUBAME2.0 supercomputer at the Tokyo Institute of Technology to discover candidates for NTDs caused by dengue virus

InterMune expects to launch Esbriet in England and Wales by the end of June...The product would potentially be used as a companion diagnostic to hypoxia-targeted therapeutics based on Threshold's drug discovery platform...HX4 to determine a patient's tumor hypoxia profile

Cancer Research Technology, the commercial arm of Cancer Research UK, and the Institute of Cancer Research, London, said they were collaborating with Janssen Biotech Inc., a unit of New Brunswick, N.J.-based Johnson & Johnson, to discover a potential new multiple myeloma drug

Another $13 million to $15 million in equipment, integration service and testing will be provided by Agila...The resolution would authorize the board to effect a share consolidation at a rate of up to 10 to 1...The compounds are thought to have relevance for Parkinson's disease

According to Soligenix, the results showed that it is possible to produce vaccines capable of withstanding temperatures at least as high as 40 degrees C (104 degrees F) for at least six months, eliminating the standard cold chain production, distribution and storage logistics required for most vaccines...UCB has an option to exclusively license rights to selected protein targets discovered by FivePrime in the collaboration

The FDA stated that bleeding rates associated with new use of Pradaxa do not appear to be higher than those with new use of warfarin, which is consistent with observations from the pivotal RE-LY trial

Sosei licensed Japanese rights to the compound from BioAlliance, which markets the product as Loramyc/Oravig...The studies are designed to allow PCT to evaluate the applicability of SistemQC technology in stem cell characterization employing Sistemic's miRNA profiling system and analytical approaches to product miRNA panels

The parties agreed to a settlement payment of $40 million, $38 million of which will be funded by Dendreon's insurers...sales and distribution rights to Abstral (fentanyl) sublingual tablets from Orexo AB, of Uppsala, Sweden...An independent assessment to confirm the diagnosis and evaluate the cause is planned

In other news, law firm Bronstein, Gewirtz & Grossman LLC, of New York, said it is investigating claims on behalf of purchasers of Spectrum securities, after shares (NASDAQ:SPPI) fell as much as 38 percent on March 13 on news that the company slashed its revenue projections for colon cancer drug Fusilev (levoleucovorin

Astellas Pharma Inc., of Tokyo, said the European Commission approved expanded options for pre-treatment prior to use of Qutenza (8 percent capsaicin patch